| Patient | Johnny Cash |
|---|---|
| Date of birth | 1932-02-26 |
| Identifiers | MRN HR-ML004-SYN-TD; SSN (made up) 000-04-8125 |
| Document date | 2003-08-14 |
| Author | Gideon Hale, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month diabetes review with glaucoma imaging. [S]
Mr. Cash returns for his six-month review. Since midodrine was raised to 5 mg he rarely feels lightheaded, only if he stands quickly after lunch, and he has had no falls. He finished physical therapy and does the home exercises most days. The low-vision therapist reviewed his home lighting, and a second stair handrail is in place. His fasting home readings run 110 to 140 mg/dL, with none below 70. He has no scalp tingling or trouble passing urine and takes the last midodrine by mid-afternoon. He uses both eye drops daily and notices no change in his vision. The FIT kit from the wellness visit has not been returned. [S]
| Element | Detail |
|---|---|
| Interval change | Rarely lightheaded on midodrine 5 mg; no falls |
| Home glucose | Fasting 110 to 140 mg/dL; none below 70 |
| Rehabilitation | Physical therapy finished; home exercises; second stair handrail fitted |
| Vision | No change noticed |
| Open items | FIT kit not returned |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 1 kg; no fever |
| Eyes | Positive | Tunnel vision, unchanged; no eye pain |
| Cardiovascular | Negative | No fainting; lightheaded only on standing quickly after lunch |
| Respiratory | Negative | No cough or breathlessness |
| Genitourinary | Negative | No difficulty passing urine |
| Endocrine | Negative | No symptoms of low glucose |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 500 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2001-05-06 to 2003-02-27 | completed | S |
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2003-02-27 | active | S |
| Sitagliptin 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2003-03-27 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2003-02-27 | active | S |
| Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtime | One drop in each eye at bedtime | Ophthalmic route | 2000-09-11 | active | S |
| Dorzolamide 2% ophthalmic solution, one drop in each eye twice daily | One drop in each eye twice daily | Ophthalmic route | 2003-02-27 | active | S |
| Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM | One tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bed | Oral route | 2003-03-27 to 2003-05-29 | completed | S |
| Midodrine 5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM | One tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bed | Oral route | 2003-05-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2003-08-14 | Body height | 188 | cm | S |
| 2003-08-14 | Body weight | 92.5 | kg | S |
| 2003-08-14 | Body mass index (BMI) [Ratio] | 26.2 | kg/m2 | S |
| 2003-08-14 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2003-08-14 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2003-08-14 | Heart rate | 72 | /min | S |
| 2003-08-14 | Respiratory rate | 16 | /min | S |
| 2003-08-14 | Body temperature | 36.6 | Cel | S |
| 2003-08-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2003-08-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.3 | % | <=5.6% | High | S |
| 2003-08-14 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2003-08-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2003-08-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.05 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2003-08-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1998)/1.73 sq M | 73 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2003-08-14 | Glucose [Mass/volume] in Serum or Plasma | 131 | mg/dL | 70-99 mg/dL | High | S |
| 2003-08-14 | Albumin/Creatinine [Mass Ratio] in Urine | 16 | mg/g | <=30 mg/g | Normal | S |
| 2003-08-14 | Right eye Intraocular pressure | 14 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2003-08-14 | Left eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2003-08-14 | Right retina Retinal nerve fiber layer.mean thickness by OCT | 60 | um | 80-120 um | Low | S |
| 2003-08-14 | Left retina Retinal nerve fiber layer.mean thickness by OCT | 57 | um | 80-120 um | Low | S |
| 2003-08-14 | Visual acuity best corrected Right eye by ETDRS eye chart | 68 | {letters} | >=80 | Low | S |
| 2003-08-14 | Visual acuity best corrected Left eye by ETDRS eye chart | 62 | {letters} | >=80 | Low | S |
Vital signs recorded on 2003-08-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and well; walks with a cane |
| Eyes | Eye clinic today: pressure 14 mmHg right and 15 mmHg left; best-corrected acuity 68 letters right and 62 left; optic nerve appearance unchanged from intake |
| Cardiovascular | Regular rhythm; blood pressure 148/82 mmHg lying, 134/74 mmHg seated, and 120/70 mmHg after three minutes standing, without symptoms |
| Feet | Skin intact; no ulcers or calluses; sensory loss to the ankles unchanged; pedal pulses present |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with diabetic autonomic neuropathy; HbA1c above the individualized goal at intake | active | confirmed | E11.43 | S — Synthetic modern diagnosis linked to the publicly reported diabetes and autonomic neuropathy. |
| Neurogenic orthostatic hypotension from diabetic autonomic neuropathy | active | confirmed | I95.1 | S — Synthetic finding; explains the autonomic symptoms once labeled Shy-Drager syndrome. |
| Diabetic distal symmetric polyneuropathy with loss of protective sensation in both feet | active | confirmed | E11.42 | S — Synthetic finding linked to his description of numb lower extremities. |
| Primary open-angle glaucoma, both eyes, severe stage | active | confirmed | H40.1133 | S — Synthetic modern diagnosis; the type and stage are not documented historically. |
| Mild nonproliferative diabetic retinopathy without macular edema, both eyes | active | confirmed | E11.3293 | S — Synthetic finding from the dilated eye examination. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
| History of recurrent pneumonia | active | confirmed | Z87.01 | S — Synthetic modern coding of the documented recurrent pneumonia; supports pneumococcal vaccination. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HbA1c | Every 3 months until at goal or after a therapy change; every 6 months when stable | Completed today | 7.3%, at goal; repeat every six months |
| Laboratory | Basic metabolic panel and urine albumin-creatinine ratio | Yearly when eGFR is 60 or more and albumin is normal | Completed today | eGFR 73; potassium 4.5; urine albumin-creatinine ratio 16 mg/g. Repeated at six months because he takes full-dose metformin and midodrine, which the kidney clears |
| Laboratory | Lipid panel | Every 3 to 12 months until stable, then yearly | Due | LDL 74 three months ago; at the annual review with lipoprotein(a) |
| Laboratory | Vitamin B12 on metformin | Periodically on long-term metformin, especially with neuropathy | Due | 286 pg/mL at intake, low-normal with neuropathy; repeat at the annual review, with methylmalonic acid if still below 300 |
| Laboratory | ALT, AST, and platelets for FIB-4 | At diagnosis and yearly | Due | AST and a platelet count added to the annual tests after the gap noted at three months |
| Examination | Blood pressure, weight, and BMI | Every visit | Completed today | Seated 134/74 mmHg; weight 92.5 kg, down 3.5 kg since intake |
| Examination | Lying, seated, and standing blood pressure | Every visit | Completed today | Lying 148/82, standing 120/70 mmHg; goal of a standing systolic pressure of 100 or more met |
| Examination | Foot examination (inspection, pulses, monofilament) | Every visit with loss of protective sensation | Completed today | No ulcer; sensory loss unchanged |
| Examination | Dental examination | Yearly | Due | No dental examination on record; advised to see his dentist |
| Examination | Tonometry (eye pressure) | Every visit | Completed today | 14 mmHg right and 15 mmHg left |
| Examination | Best-corrected visual acuity | Each comprehensive eye examination | Completed today | 68 letters right and 62 left, against 68 and 63 at intake |
| Examination | Drop adherence, ocular surface, and systemic effects of glaucoma drops | Every visit | Completed today | Both drops used daily; no ocular surface irritation; no systemic effect |
| Imaging | OCT of the optic nerve and nerve fiber layer | Every 6 to 12 months; every 6 months in severe glaucoma | Completed today | 60 µm right and 57 µm left, against 61 and 57 at intake: no structural progression |
| Survey | Visual field (Humphrey 24-2) | Every 6 to 12 months | Completed today | No new defect against intake |
| Survey | Visual field (Humphrey 10-2) | In advanced disease, alongside the 24-2 | Deferred | Not done at intake or today, a deviation from the protocol for severe glaucoma. The 24-2 and OCT are stable, so loss near fixation is unlikely to have been missed; the eye clinic will add a 10-2 at the next field visit |
| Examination | Gonioscopy and corneal thickness | At the initial evaluation; repeat only with an unexplained pressure change | Not indicated | Baseline measures belong to the eye clinic's initial evaluation; the pressure response has been as expected |
| Survey | Hypoglycemia review and home glucose log | Every visit | Completed today | No readings below 70 mg/dL |
| Survey | Diabetes distress, anxiety (GAD-7), disordered eating, and social needs screens | Yearly | Due | Not yet done this year; at the annual review |
| Survey | Cognitive screen and fall risk | Yearly at 65 or older | Up to date | Mini-Cog 5 of 5 at intake; Timed Up and Go 14 seconds at the wellness visit |
| Survey | 10-year cardiovascular risk (PREVENT) | Yearly from 40 to 75 without cardiovascular disease | Not indicated | He already takes a high-intensity statin for diabetes with complications, so the score would not change treatment |
| Survey | Tobacco use | Every visit | Completed today | No tobacco use |
| Medication safety | Midodrine safety: lying pressure, timing, and urinary retention | Every visit on midodrine | Completed today | Lying 148/82 mmHg; no retention |
| Medication safety | Vaccination review | Yearly, and as doses fall due | Due | Recombinant zoster dose 2 is due within six months of dose 1, at his pharmacy, alongside the seasonal influenza vaccine; RSV and COVID-19 before the respiratory season; tetanus booster |
| Referral | Diabetes self-management education and medical nutrition therapy | At diagnosis, yearly, with new complications, and at care transitions | Referred | Not arranged in the first six months despite two medication changes, a deviation from the protocol. No harm resulted, since HbA1c reached goal without hypoglycemia. Referred today to an individual program with large-print materials because of his vision |
| Self-management | Exercise, diet, orthostatic measures, and foot self-care | Every visit | Completed today | Home exercises most days; smaller lunches; daily foot checks |
Goal progress:
Guideline basis: Standards of Care in Diabetes—2025 (2025); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026)
Follow-up: Eye clinic review in three to six months. Diabetes review in six months with HbA1c. Annual review with lipids, lipoprotein(a), vitamin B12, AST, platelet count, and the yearly screens. [S]